InvestorsHub Logo
Followers 45
Posts 5703
Boards Moderated 0
Alias Born 10/28/2009

Re: DR5 post# 1557

Wednesday, 09/12/2018 8:27:40 AM

Wednesday, September 12, 2018 8:27:40 AM

Post# of 14014
"This study is a prospective, non-inferiority, multi-center, randomized, open-label trial to compare HemoStyp with Surgicel® in the management of bleeding during surgery."

https://www.clinicaltrials.gov/ct2/show/NCT03654560?term=united+health+products+inc&rank=1

Primary Outcome Measures :
Non-inferiority of HemoStyp versus Surgicel [ Time Frame: 10 minutes ]
Time to hemostasis from start of study treatment at target bleeding site until 10 minutes after treatment initiation. The non-inferiority of HemoStyp versus Surgicel will be evaluated. If the criteria for non-inferiority are satisfied, a superiority analysis will be performed.

Let the chips fall where they may! Smell a strong buyout rumor $4.50/sh!

GO UEEC!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent UEEC News